At the news
? MIXEDIMPACT 6/10 SC TO-C filed Sep 24, 2026 at 17:11 ET
Utah Medical Products (UTMD) commenced an issuer tender offer to repurchase up to 650,000 shares at $75.00 per share, representing a 17% premium over the 12-month average closing price and a 21% premium over the 24-month average. The offer comes as the company disclosed that first-half 2026 sales and net profits declined 12% and 13% year-over-year, respectively. Management views the stock as undervalued and believes the buyback will enhance remaining shareholders' value, but the concurrent revenue and profit decline signals underlying operational weakness.
- UTMD offers to buy up to 650,000 shares at $75.00 per share, a 17% premium over the 12-month average closing price and a 21% premium over the 24-month average.
- First-half 2026 sales declined 12% and net profits declined 13% versus the same period in 2025.
- EBITDA for the most recent twelve months (last half of 2025 + first half of 2026) was $15,703,744.
- The tender offer expires on October 7, 2026, unless extended.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access